August 24, 2012 In the past month following China’s implementation of the revised hazardous chemicals (HC) registration decree (SAWS Order 53 of 2012), many a company registrant was wandering whether they could put a commissioned telephone number for the required emergency consulting obligation. Some received the NRCC reply that this special phone number should not be consigned to “unofficial” chemical research institutes or service agents as it used to be under the 2002 legislative version. Then, what entities are allowed to undertake the emergency consulting service for company registrants? What do the new rules say about it?Subtle changes made to the policy of emergency phone service for China’s new hazardous chemicals registration are making some registrants confused: How do I arrange my emergency phone service in view of China’s new hazardous chemicals registration?
August 23, 2012 The recently released “Measures for the Administration of Registration of Hazardous Chemicals” (SAWS Order 53) has just come into force in China on Aug 1st, 2012. Besides the attention-grabbing changes in the regulated scope (“Catalogue of hazardous chemicals in China”), legal entity (both manufacturers and importers are included for registration) and registration contents, SAWS will impose more severe punishment on those who do not comply with this newly released Measures.SAWS to Enforce More Severe Punishment for Non-Compliance of the Revised HC Registration Measures
On 2 August 2012, China’s State Food and Drug Administration (SFDA) issued the Regulation on Strengthening Pharmaceutical Excipients Supervision in a press conference (hereinafter referred to as the “Regulation”), which will come into effect since 1 February 2013. Under the Regulation, the respective duties and obligations of pharmaceutical manufacturers and excipient manufacturers are specified accordingly. The pharmaceutical manufacturers will take the primary responsibility for illegal use of excipients in producing drugs and should assure the quality of excipients purchased from their excipient suppliers. So pharmaceutical manufacturers are required to fortify the quality management system and sign quality agreement with the main suppliers in the Regulation. The pharmaceutical excipient manufacturers should strictly comply with the Good Manufacturing Practice (GMP) for Pharmaceutical Excipients in the process of production, while which being effective since 2006 is only taken as a voluntary standard before the issue of the Regulation.China published regulations on pharmaceutical excipients supervision to realize full supervision of the pharmaceutical production and supply chain since 1 February 2013.